Drugs / NDV-HXP-S
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04993209 | Jul → Dec 2021 | COVID-19 | Butantan Institute | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05354024 | Feb → Oct 2023 | Coronaviridae infectious disease | Butantan Institute | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT05181709 Comparator | Feb 2022 → May 2023 | COVID-19 | Sean Liu | Completed | No outcome recorded |
| Phase 1/2 | NCT04764422 Comparator | Mar 2021 → Sep 2022 | COVID-19, severe acute respiratory syndrome, viral pneumonia | Mahidol University | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-08-10 | Institute of Vaccines and Medical Biologicals, Vietnam | Results A Newcastle disease virus-vector expressing a prefusion-stabilized spike protein of SARS-CoV-2 induces protective immune responses against prototype virus and variants of concern in mice and hamsters com.vn ↗
The immunity conferred by NDV-HXPS effectively counteracts SARS-CoV-2 infection in mice and hamsters. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-08-10 | Institute of Vaccines and Medical Biologicals, Vietnam | A Newcastle disease virus-vector expressing a prefusion-stabilized spike protein of SARS-CoV-2 induces protective immune responses against prototype virus and variants of concern in mice and hamsters com.vn ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NDV-HXP-S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05181709 ↗ |
| Modality | Vaccine | “NDV-HXP-S is an inactivated egg-based recombinant Newcastle disease virus vaccine expressing the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).” PMID 35284808 ↗ Mar 2022 |
| Route | Intramuscular | “35 subjects age 18-59 will receive NDV-HXP-S 1 µg study vacine administered 0.5 mL IM” NCT04764422 ↗ |